Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

136.74 +1.47 (+1.08%)
Streaming Delayed Price Updated: 12:08 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
52 53 Next >
News headline image
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report ↗
Two of the three companies easily beat sales and earnings expectations, but sales fell for the third. 
Via Investor's Business Daily
Rancho Biosciences Welcomes BenevolentAI as New Member to Its Single Cell Data Science Consortium
SAN DIEGO, February 1, 2023 (Newswire.com) - On Feb. 26, 2022, Rancho Biosciences, a leading data sciences services company, launched its Single Cell Data Science (SCDS) pre-competitive consortium,... 
Via Newswire.com
News headline image
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors ↗
Futures trading point to a negative start by Wall Street stocks on Wednesday as traders exercise restraint ahead of the Fed decision due in the afternoon. Cues From Tuesday’s Trading: 
Via Benzinga
News headline image
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off ↗
 
Via Benzinga
News headline image
A Preview Of Novartis's Earnings ↗
 
Via Benzinga
Hopeful Golden Cross Forms On Novartis's Chart ↗
 
Via Benzinga
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 1, 2023 ↗
Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion. 
Via Benzinga
Envision Pharma Group Hires Leading Industry Executives Dominic Marasco and Gregory Carpenter to Lead Further Expansion of the Business and Support Growing Customer Demand
PHILADELPHIA, January 31, 2023 (Newswire.com) - Envision Pharma Group (Envision) today announced the appointment of two senior executives while further expanding its global focus on M&A,... 
Via Newswire.com
News headline image
7 CRISPR Stocks With the Best Long-Term Potential ↗
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
News headline image
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump ↗
Koninklijke Philips NV (NYSE: PHG) would reduce its workforce by an additional 6,000 roles globally by 2025, of which 3,000 will be implemented in 2023 to restore its profitability following a recall... 
Via Benzinga
News headline image
Could This Be Novartis' Next Blockbuster Medicine? ↗
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug. 
Via The Motley Fool
News headline image
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
News headline image
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
News headline image
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗
 
Via Benzinga
News headline image
3 Drug Stocks With Promising Pipelines for 2023 ↗
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors. 
Via InvestorPlace
News headline image
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem. 
Via Benzinga
News headline image
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide ↗
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.  
Via Benzinga
News headline image
National Advertising Division Finds Novartis Breast Cancer Drug Claim Supported in Physician-Directed Messaging, But Not in Ads to Consumers
Via iCrowdNewswire
News headline image
Drug Delivery Market – Major Technology Giants in Buzz Again : Johnson & Johnson, Sanofi, Pfizer
How to reach that market place and its associated audience with current marketing efforts? Benchmark now the competitive efforts with high growth emerging players and leaders of Drug Delivery Market. 
Via SBWire
News headline image
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Global Cell and Gene Therapy Market will worth USD 21,508 million by 2028-end at a CAGR of 28.2% from 2022 to 2028 according to Intelligence Market Report 
Via SBWire
News headline image
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units ↗
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology. 
Via Benzinga
News headline image
3 Biotech Companies to Watch in 2023 ↗
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year. 
Via InvestorPlace
News headline image
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
These two pharmaceutical companies pay market-beating dividends to shareholders. 
Via The Motley Fool
News headline image
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.' 
Via Benzinga
News headline image
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗
These two biotechs are flying high right now. 
Via The Motley Fool
News headline image
Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug ↗
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.